Washington University in St. Louis (WU)
Our group is interested in developing predictive and prognostic biomarkers in patients with non-small cell lung cancer(NSCLC). We have identified a 64 gene signature that accurately predicts the outcomes of patients with resected early stage NSCLC. We are in the process of developing a q RT PCR assay that could be performed in formalin fixed paraffin embedded tissues. We are also pursuing genomic predictors of recurrence in the brain as brain metastases from NSCLC is a major cause of morbidity and mortality. We are actively studying distinctive molecular changes associated with lung cancer in lifelong never smokers. Finally, our group is interested in exploring novel agents in the treatment of advanced NSCLC.